{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:17Z","timestamp":1790821517957,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.clinthera.2004.11.014","type":"journal-article","created":{"date-parts":[[2005,1,6]],"date-time":"2005-01-06T07:15:12Z","timestamp":1104995712000},"page":"1728-1757","source":"Crossref","is-referenced-by-count":53,"title":["Daptomycin: A cyclic lipopeptide antimicrobial agent"],"prefix":"10.1016","volume":"26","author":[{"given":"LilyAnn","family":"Jeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horatio B.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2004.11.014_bib1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2165\/00003495-200363140-00003","article-title":"A practical guide to the treatment of complicated skin and soft tissue infections","volume":"63","author":"Fung","year":"2003","journal-title":"Drugs"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2004.11.014_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/44.suppl_1.19","article-title":"Optimal treatment of complicated skin and skin structure infections","volume":"44","author":"Nichols","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib3","first-page":"624","article-title":"Reduced susceptibility of Staphylococcus aureus to vancomycin\u2014Japan, 1996","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2004.11.014_bib4","first-page":"765","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin\u2014United States, 1997","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2004.11.014_bib5","first-page":"813","article-title":"Update: Staphylococcus aureus with reduced susceptibility to vancomycin\u2014United States, 1997","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2004.11.014_bib6","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2014United States, 2002","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2004.11.014_bib7","series-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","first-page":"1342","article-title":"Vancomycin-Resistant Staphylococcus aureus Investigative Team","volume":"348","author":"Chang","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.014_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/382357","article-title":"Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure","volume":"38","author":"Whitener","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib9","first-page":"902","article-title":"Vancomycin-resistant Staphylococcus aurus\u2014Pennsylvania, 2002","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2004.11.014_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.48.1.275-280.2004","article-title":"Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania","volume":"48","author":"Tenover","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib11","first-page":"322","article-title":"Vancomycin-resistant Staphylococcus aureus\u2014New York, 2004","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2004.11.014_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0163-4453(94)95680-4","article-title":"Endocarditis due to high level gentamicin resistant Enterococcus faecium","volume":"28","author":"Das","year":"1994","journal-title":"J Infect"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2004.11.014_bib13","first-page":"iii23","article-title":"Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections","volume":"51","author":"Kauffman","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0196-6553(99)70031-3","article-title":"National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990\u2013May 1999, issued June 1999","volume":"27","year":"1999","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.clinthera.2004.11.014_bib15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(00)04376-2","article-title":"Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid","volume":"357","author":"Gonzales","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2004.11.014_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM200203143461121","article-title":"Nosocomial spread of linezolid-resistant, vancomycin resistant Enterococcus faecium","volume":"346","author":"Herrero","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2004.11.014_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jac\/dkf246","article-title":"Linezolid-resistant enterococci: Report of the first isolates in the United Kingdom","volume":"50","author":"Auckland","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2004.11.014_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/380465","article-title":"Delayed discovery of linezolid-resistant, vancomycin-resistant Enterococcus faecium: Lessons learned","volume":"38","author":"Schwartz","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib20","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1086\/374929","article-title":"Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid","volume":"36","author":"Rahim","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0732-8893(01)00333-9","article-title":"Linezolid-resistant Enterococums faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRYAntimicrobial Surveillance Program","volume":"42","author":"Jones","year":"2002","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0732-8893(03)00012-9","article-title":"Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRYAntimicrobial Surveillance Program (1997\u20132000)","volume":"46","author":"Mutnick","year":"2003","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib23","series-title":"Application number 21\u2013572. Administrative Document(s)","author":"Center for Drug Evaluation and Research","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.014_bib24","series-title":"Cubicin [package insert]","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.014_bib25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.7164\/antibiotics.41.1093","article-title":"Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: The synthesis and evaluation of daptomycin (LY146032)","volume":"41","author":"Debono","year":"1988","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.clinthera.2004.11.014_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7164\/antibiotics.40.761","article-title":"A21978C, a complex of new acidic peptide antibiotics: Isolation, chemistry, and mass spectral structure elucidation","volume":"40","author":"Debono","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.clinthera.2004.11.014_bib27","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/AAC.31.7.1093","article-title":"Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032","volume":"31","author":"Allen","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0005-2736(86)90217-8","article-title":"The role of acyl chain character and other determinants on the bilayer activity of A21978C an acidic lipopeptide antibiotic","volume":"859","author":"Lakey","year":"1986","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.clinthera.2004.11.014_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0005-2736(89)90104-1","article-title":"The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions","volume":"985","author":"Lakey","year":"1989","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.clinthera.2004.11.014_bib31","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1021\/bi00413a009","article-title":"Fluorescence indicates a calcium dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes","volume":"27","author":"Lakey","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.clinthera.2004.11.014_bib32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.30.4.532","article-title":"In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic","volume":"30","author":"Eliopoulus","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.chembiol.2004.04.020","article-title":"Structural transitions as determinants of the action of the calcium dependent antibiotic daptomycin","volume":"11","author":"Jung","year":"2004","journal-title":"Chem Biol"},{"key":"10.1016\/j.clinthera.2004.11.014_bib34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.chembiol.2004.07.001","article-title":"Daptomycin structure and mechanism of action revealed","volume":"11","author":"Micklefield","year":"2004","journal-title":"Chem Biol"},{"key":"10.1016\/j.clinthera.2004.11.014_bib35","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1128\/AAC.35.11.2282","article-title":"Daptomycin disrupts membrane potential in growing Staphylococcus aureus","volume":"35","author":"Alborn","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib36","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1128\/AAC.35.12.2639","article-title":"Inhibition of membrane potential-dependent amino acid transport by daptomycin","volume":"35","author":"Allen","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib37","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.34.6.1220","article-title":"Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY146032)","volume":"34","author":"Canepari","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/31.2.227","article-title":"The activity of daptomycin on Enterococcus faecium protoplasts: Indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis","volume":"31","author":"Boaretti","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib39","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1128\/AAC.39.9.2068","article-title":"Identification of daptomycinbinding proteins in the membrane of Enterococcus hirae","volume":"39","author":"Boaretti","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/mdr.1996.2.85","article-title":"Lipoteichoic acid as a target for antimicrobial action","volume":"2","author":"Canepari","year":"1996","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.clinthera.2004.11.014_bib41","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1128\/AAC.47.8.2682-2684.2003","article-title":"In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococms faecalis are not mediated by inhibition oflipoteichoic acid biosynthesis","volume":"47","author":"Laganas","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1099\/00222615-30-1-45","article-title":"Scanning electron-microscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin","volume":"30","author":"Wale","year":"1989","journal-title":"J Med Microbial"},{"key":"10.1016\/j.clinthera.2004.11.014_bib43","first-page":"15","article-title":"The effects of daptomycin on chemical composition and morphology of Staphylococcus aureus","volume":"78","author":"Conrad","year":"1998","journal-title":"Proc Ohla Acad Sci"},{"key":"10.1016\/j.clinthera.2004.11.014_bib44","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","article-title":"Single-dose phamacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Woodworth","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib45","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib46","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1128\/AAC.35.12.2505","article-title":"Effect of protein binding of daptomycin on MIC and antibacterial activity","volume":"35","author":"Lee","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib49","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1128\/AAC.36.12.2611","article-title":"Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium","volume":"36","author":"Caron","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib50","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1128\/AAC.47.5.1714-1718.2003","article-title":"Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"47","author":"Sakoulas","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1128\/AAC.40.1.203","article-title":"Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration","volume":"40","author":"Michiels","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib52","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/AAC.39.5.1134","article-title":"In vivo verification of in vitro model of antibiotic treatment of device-related infection","volume":"39","author":"Blaser","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.46.1.31-33.2002","article-title":"Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers","volume":"46","author":"Wise","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jac\/dkg277","article-title":"Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus","volume":"52","author":"Vaudaux","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/106002809002400309","article-title":"Clinical pharmacokinetics of daptomycin","volume":"24","author":"Pryka","year":"1990","journal-title":"DICP"},{"key":"10.1016\/j.clinthera.2004.11.014_bib56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jac\/33.3.655","article-title":"Tobramycin and daptomycin disposition when co-administered to healthy volunteers","volume":"33","author":"Woodworth","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib57","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/AAC.36.5.1109","article-title":"Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis andbacteremia","volume":"36","author":"Rybak","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib58","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib59","series-title":"Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacokinetics (PK) and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease (ESRD)","author":"Dvorchik","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.014_bib60","series-title":"Abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy","article-title":"Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease","author":"Sica","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.014_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/0091270004266619","article-title":"Moderate liver impairment has no influence on daptomycin pharmacokinetics","volume":"44","author":"Dvorchik","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2004.11.014_bib62","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0091270004265646","article-title":"Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers","volume":"44","author":"Dvorchik","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2004.11.014_bib63","series-title":"Approval package for: Application number 21\u2013572. Clinical pharmacology biopharmaceutics review","author":"Center for Drug Evaluation and Research","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.014_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0732-8893(00)00164-4","article-title":"Daptomycin susceptibility tests: Interpretive criteria, quality control, and effect of calcium on in vitro tests","volume":"38","author":"Fuchs","year":"2000","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib65","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.014_bib66","series-title":"Approval package for: Application number 21-572. Micro biology review(s)","author":"Center for Drug Evaluation and Research","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.014_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/dkg288","article-title":"The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species","volume":"52","author":"Richter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib68","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1128\/AAC.47.11.3561-3566.2003","article-title":"Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection","volume":"47","author":"Alder","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/48.4.563","article-title":"Activity of daptomycin against Gram-positive pathogens: A comparison with other agents and the determination of a tentative breakpoint","volume":"48","author":"Wise","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib70","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkg130","article-title":"Activity of daptomycin against susceptible and multidrugresistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000\u20132001","volume":"51","author":"Critchley","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib71","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1128\/AAC.47.5.1689-1693.2003","article-title":"Baseline study to determine in vitro activities of daptomycin against gram- positive pathogens isolated in the United States in 2000\u20132001","volume":"47","author":"Critchley","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib72","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkh143","article-title":"Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms","volume":"53","author":"Streit","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib73","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jac\/48.2.219","article-title":"The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates","volume":"48","author":"King","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib75","series-title":"Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Killing activity of daptomycin against vancomycin-intermediate Staphylococcus aureus (VISA) and hetero-VISA (hVISA)","author":"Howe","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.014_bib76","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib77","series-title":"Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"In vitro activity of ABT 773, telithromycin and daptomycin against group C and G streptococci","author":"Klein","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.014_bib78","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib79","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1128\/AAC.47.12.3960-3963.2003","article-title":"Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitropharmacodynamic model with simulated endocardial vegetations","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/AAC.45.2.454-459.2001","article-title":"Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus,vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"45","author":"Akins","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib81","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.36.10.2334","article-title":"Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model","volume":"36","author":"Vance-Bryan","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib82","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0732-8893(88)90100-9","article-title":"In vitro activity of LY146032 against gram-positive bacteria","volume":"9","author":"Silva","year":"1988","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib83","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/BF01984930","article-title":"Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model","volume":"10","author":"Bingen","year":"1991","journal-title":"Eur J Clin Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib84","series-title":"Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Bactericidal activity of daptomycin against clinical isolates of linezolid\/vancomycin-resistant Enterococcus faecium","author":"Jain","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.014_bib85","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/AAC.47.9.3012-3014.2003","article-title":"Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates","volume":"47","author":"Pankuch","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib86","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/AAC.35.9.1710","article-title":"Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killingand postantibiotic effect and influence of Ca2+ and albumin on these drugs","volume":"35","author":"Hanberger","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib87","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","article-title":"Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model","volume":"52","author":"Dandekar","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib88","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/AAC.31.8.1199","article-title":"Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis","volume":"31","author":"Miniter","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib89","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jac\/dkh104","article-title":"Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci","volume":"53","author":"Rand","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0732-8893(92)90045-U","article-title":"In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model","volume":"15","author":"Rice","year":"1992","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib91","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jac\/19.4.445","article-title":"In vitro activity of LY 146032, a novel cyclic lipopeptide, alone and in combination with gentamicin or tobramycin against enterococci","volume":"19","author":"Watanakunakorn","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib92","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.48.8.2871-2875.2004","article-title":"Synergy of daptomycin with oxacillin and other \u03b2-lactams against methicillin-resistant Staphylococcus aureus","volume":"48","author":"Rand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib93","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/AAC.45.6.1799-1802.2001","article-title":"Resistance studies with daptomycin","volume":"45","author":"Silverman","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib94","series-title":"Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Determination of synergistic effects of daptomycin with gentamicin or in vitro effect of beta lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and time-kill kinetics","author":"Snydman","year":"2001"},{"key":"10.1016\/j.clinthera.2004.11.014_bib95","series-title":"Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Analysis of the mechanisms of daptomycin resistance in Staphylococcus aureus","author":"Kaatz","year":"2001"},{"key":"10.1016\/j.clinthera.2004.11.014_bib96","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.33.7.1019","article-title":"Treatment of experimental endocarditis caused by a \u03b2-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin","volume":"33","author":"Hindes","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib97","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/AAC.34.11.2081","article-title":"Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis","volume":"34","author":"Kaatz","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib98","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1128\/AAC.34.12.2348","article-title":"Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role oftest conditions in this determination","volume":"34","author":"Cantoni","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib99","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/BF01967482","article-title":"Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin","volume":"8","author":"Luu","year":"1989","journal-title":"Eur J Clin Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib100","series-title":"Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Efficacy of a high-dose regimen of daptomycin compared to oxacillin and vancomycin in the therapy of experi mental foreign body infection due to methicillin-suscephble Staphylococcus aureus","author":"Vaudaux","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.014_bib101","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1128\/AAC.33.8.1280","article-title":"Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity","volume":"33","author":"Wood","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.32.1.81","article-title":"LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelo nephritis in the rat model","volume":"32","author":"Sapico","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib103","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/AAC.32.6.877","article-title":"Daptomycin (LY146032) treatment of experimental enterococcal endocarditis","volume":"32","author":"Bush","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib104","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1128\/AAC.36.9.1864","article-title":"Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endo carditis caused by penicillin-resistant enterococci","volume":"36","author":"Ramos","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib105","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.33.5.689","article-title":"Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureusosteomyelitis in rabbits","volume":"33","author":"Mader","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.34.2.245","article-title":"Staphylococcus aureus ventriculitis treated with singledose intraventricular vancomycin or daptomycin (LY146032): Bacterial and antibiotic kinetics in hydrocephalic rabbits","volume":"34","author":"Haworth","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/21.1.33","article-title":"Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"21","author":"Kephart","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib108","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000238615","article-title":"LY146032 in a hamster model of Staphylococcus aureus pneumonia effect on in vivo clearance and mortality and in vitro opsonophagocytic killing","volume":"34","author":"Verghese","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2004.11.014_bib109","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.31.7.1135","article-title":"Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032","volume":"31","author":"Dong","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib110","series-title":"Abstracts of the IDSA 40th Annual Meeting","article-title":"Rapid bactericidal action of daptomycin against septicemia induced by gram positive bacteria in mice","author":"Li","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.014_bib111","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000238800","article-title":"Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model","volume":"36","author":"Smith","year":"1990","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2004.11.014_bib112","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.32.3.337","article-title":"Impact of LY146032 on Streptococcus (Enterococcus) faecalis translocation in mice","volume":"32","author":"Dougherty","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib113","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/AAC.38.2.189","article-title":"Subcellular distribution of daptomycin given alone or with tobramycin in renal proximal tubular cells","volume":"38","author":"Beauchamp","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0005-2736(95)00082-E","article-title":"Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin; an infrared spectroscopic investigation","volume":"1237","author":"Gurnani","year":"1995","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.clinthera.2004.11.014_bib115","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1021\/bi971793d","article-title":"Modulation of phospholipase A2 activity among aminoglycosides and daptomycin: A Fourier transform infrared spectroscopy study","volume":"37","author":"Carrier","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.clinthera.2004.11.014_bib116","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1128\/AAC.38.4.742","article-title":"Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin","volume":"38","author":"Couture","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib117","series-title":"Approval package for: Application number 21\u2013572. Medical Review(s)","author":"Center for Drug Evaluation and Research","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.014_bib118","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.014_bib119","series-title":"Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Clinical significance of dual infection (DI) with Staphylococcus aureus (SA) and hemolytic streptococci (hStr) in com plicated skin and soft tissue infections (cSSTI): Results from daptomycin (DAP) trial 99-01","author":"Rodin","year":"2001"},{"key":"10.1016\/j.clinthera.2004.11.014_bib120","series-title":"Abstracts of the IDSA 39th Annual Meeting","article-title":"Faster resolution of clinical signs (CSx) in complicated skin and soft tissue infection (cSSTI) by daptomycin (DAP) vs standard therapy (STND) in arandomized, blinded, comparative study","author":"Matthews","year":"2001"},{"key":"10.1016\/j.clinthera.2004.11.014_bib121","series-title":"Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Daptomycin","author":"Snydman","year":"2000"},{"key":"10.1016\/j.clinthera.2004.11.014_bib122","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jac\/47.3.364","article-title":"Daptomycin for line-related Leuconostoc bacteraemia","volume":"47","author":"Golan","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib123","doi-asserted-by":"crossref","first-page":"2948 2953.","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Oncedaily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib124","series-title":"Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Skeletal muscle effects in patients receiving once-daily daptomycin (DAP) for complicated skin and skin structure infec tion (cSSSI)","author":"Knapp","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.014_bib125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/25.4.635","article-title":"Experimental studies on nephrotoxicity and pharmacokinetics of LY146032 (daptomycin) in rats","volume":"25","author":"Kreft","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.014_bib126","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.014_bib127","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1128\/AAC.47.12.3764-3767.2003","article-title":"Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model","volume":"47","author":"Hermsen","year":"2003","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0149291804803394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0149291804803394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T05:56:03Z","timestamp":1548827763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0149291804803394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":127,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["0149291804803394"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2004.11.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}